Seres Therapeutics is a biotechnology business based in the US. Seres Therapeutics shares (MCRB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.69 – an increase of 16.26% over the previous week. Seres Therapeutics employs 233 staff and has a trailing 12-month revenue of around $126.3 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.69 |
|---|---|
| 52-week range | $0.54 - $2.05 |
| 50-day moving average | $0.86 |
| 200-day moving average | $0.91 |
| Wall St. target price | $3.87 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.19 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.5789 from 2024-11-18
| 1 week (2024-11-13) | -1.91% |
|---|---|
| 1 month (2024-10-18) | -31.67% |
| 3 months (2024-08-20) | -32.77% |
| 6 months (2024-05-20) | -39.00% |
| 1 year (2023-11-20) | -40.33% |
|---|---|
| 2 years (2022-11-18) | -91.49% |
| 3 years (2021-11-19) | 9.16 |
| 5 years (2019-11-20) | 3.865 |
| Revenue TTM | $126.3 million |
|---|---|
| Gross profit TTM | $-165,792,000 |
| Return on assets TTM | -9.7% |
| Return on equity TTM | -1556.28% |
| Profit margin | -20.17% |
| Book value | $0.18 |
| Market Capitalization | $100.8 million |
TTM: trailing 12 months
We're not expecting Seres Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Seres Therapeutics's shares have ranged in value from as little as $0.54 up to $2.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seres Therapeutics's is 2.05. This would suggest that Seres Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Seres Therapeutics, Inc. , a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.